share_log

Cano Health Analyst Ratings

Benzinga ·  Aug 14, 2023 08:07
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/14/2023 21.83% Credit Suisse $2.5 → $0.5 Maintains Neutral
08/11/2023 Jefferies Downgrades Buy → Hold
08/11/2023 94.93% Citigroup $4 → $0.8 Downgrades Buy → Neutral
05/16/2023 143.66% Piper Sandler $0.5 → $1 Maintains Underweight
05/12/2023 509.16% Credit Suisse → $2.5 Reiterates Neutral → Neutral
01/06/2023 204.58% UBS $12 → $1.25 Downgrades Buy → Neutral
01/05/2023 Wolfe Research Downgrades Outperform → Peer Perform
12/13/2022 265.5% B of A Securities → $1.5 Reinstates → Underperform
11/16/2022 1118.32% Citigroup $7 → $5 Maintains Buy
11/10/2022 630.99% Cowen & Co. $10 → $3 Downgrades Outperform → Market Perform
11/10/2022 Raymond James Downgrades Outperform → Market Perform
10/27/2022 1118.32% Credit Suisse $10 → $5 Downgrades Outperform → Neutral
09/07/2022 1605.65% Truist Securities → $7 Initiates Coverage On → Hold
08/10/2022 874.66% Piper Sandler $4 → $4 Maintains Underweight
06/24/2022 1849.32% Raymond James → $8 Initiates Coverage On → Outperform
06/15/2022 1361.99% B of A Securities $8 → $6 Downgrades Buy → Neutral
05/11/2022 2336.65% Credit Suisse $13 → $10 Maintains Outperform
05/11/2022 874.66% Piper Sandler $5 → $4 Maintains Underweight
05/10/2022 1849.32% Citigroup $10 → $8 Maintains Buy
05/03/2022 1849.32% B of A Securities → $8 Initiates Coverage On → Buy
04/20/2022 3554.97% UBS → $15 Initiates Coverage On → Buy
04/06/2022 1118.32% Piper Sandler $8.5 → $5 Downgrades Neutral → Underweight
03/16/2022 3067.64% Credit Suisse $15 → $13 Maintains Outperform
11/10/2021 3067.64% Piper Sandler $11 → $13 Maintains Neutral
10/20/2021 4042.3% Jefferies → $17 Initiates Coverage On → Buy
10/19/2021 2580.31% Piper Sandler → $11 Initiates Coverage On → Neutral
10/01/2021 4529.63% Wolfe Research → $19 Initiates Coverage On → Outperform
09/21/2021 4773.29% Citigroup → $20 Initiates Coverage On → Buy
09/10/2021 4285.96% Cowen & Co. → $18 Initiates Coverage On → Outperform
08/02/2021 4285.96% Credit Suisse → $18 Initiates Coverage On → Outperform

What is the target price for Cano Health (CANO)?

The latest price target for Cano Health (NYSE: CANO) was reported by Credit Suisse on August 14, 2023. The analyst firm set a price target for $0.50 expecting CANO to rise to within 12 months (a possible 21.83% upside). 13 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Cano Health (CANO)?

The latest analyst rating for Cano Health (NYSE: CANO) was provided by Credit Suisse, and Cano Health maintained their neutral rating.

When is the next analyst rating going to be posted or updated for Cano Health (CANO)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cano Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cano Health was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.

Is the Analyst Rating Cano Health (CANO) correct?

While ratings are subjective and will change, the latest Cano Health (CANO) rating was a maintained with a price target of $2.50 to $0.50. The current price Cano Health (CANO) is trading at is $0.41, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment